112
Views
19
CrossRef citations to date
0
Altmetric
Original Research

Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study

, , &
Pages 449-456 | Published online: 24 Apr 2013

Figures & data

Figure 1 Injection sites: A, procerus muscle; B, right medial corrugator muscle; C, left medial corrugator muscle; D, right lateral corrugator muscle; E, left lateral corrugator muscle.

Figure 1 Injection sites: A, procerus muscle; B, right medial corrugator muscle; C, left medial corrugator muscle; D, right lateral corrugator muscle; E, left lateral corrugator muscle.

Table 1 Patient demographics

Figure 2 Percentage of responders over time (A) when a responder was defined as a patient with at least a 1-point improvement from baseline at rest and at maximum frown; (B) when a responder was defined as a patient with at least a 2-point improvement from baseline at maximum frown.

Figure 2 Percentage of responders over time (A) when a responder was defined as a patient with at least a 1-point improvement from baseline at rest and at maximum frown; (B) when a responder was defined as a patient with at least a 2-point improvement from baseline at maximum frown.

Figure 3 Mean change from baseline glabellar frown lines score on the 5-point scale at maximum frown over time.

Note: *P < 0.001.
Figure 3 Mean change from baseline glabellar frown lines score on the 5-point scale at maximum frown over time.

Table 2 Percentage of patients who assessed themselves as having “improved” or “markedly improved” glabellar frown lines compared with baseline

Table 3 Patient questionnaire responses: mean percentage of patients who agreed with the statements at the time points shown